# Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

> **NCT00369343** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 381 (actual)

## Conditions studied

- Depression
- Depressive Disorder
- Depressive Disorder, Major

## Interventions

- **DRUG:** Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00369343
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-11
- **Final completion:** 2008-07
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369343, "Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00369343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*